An Association Between HBoV and Acute Gastroenteritis in a 2-Month-Old Infant: A Case Report
Abstract
Introduction: The Human bocavirus (HBoV) was first identified from the nasopharyngeal aspirate specimen in 2005, which includes four subtypes (HBoV1-4). The HBoV-1 is a major subtype in acute respiratory infections of children, and others (HBoV2-4) present in the stool specimens. The pathogenic role of HBoV2-4 in acute gastroenteritis has not confirmed yet, therefore, it has been considered widely. Case Presentation: In this report, we presented a 2-month-old boy with acute gastroenteritis admitted to the Shahid Beheshti Hospital of Kashan, Iran. The stool sample of the patient was tested for HBoV by polymerase chain reaction (PCR) of the NP-1 gene. The other major gastrointestinal pathogens of Salmonella spp., Shigella spp., Giardia lamblia, and Entamoeba histolytica were confirmed by specialized microbiological procedures and viral pathogen of Rotavirus by the enzyme-linked immunosorbent assay. This case was confirmed by NP-1 plasmid cloned as a positive control. All clinical manifestations were analyzed by a pediatric nurse through hospital admission. Conclusions: This case was found HBoV-positive for the NP-1 gene of 354 bp by PCR. The major signs were diarrhea, fever, dehydration, and abdominal pain. This case was charged after supportive therapies for dehydration. We showed that HBoV could be a gastrointestinal pathogen in pediatric patients and causing diarrhea in young children. However, more studies are needed to confirm.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.